Myriad Genetics Stock

Myriad Genetics EBITDA per Share

The EBITDA per Share of Myriad Genetics (MYGN) as of Aug 15, 2026 is -0.73 USD. In the previous year, EBITDA per Share was -1.34 USD — a change of -45.91% (higher).

EBITDA per Share

-0.73USD

YoY

-45.91%

Last updated:

EBITDA per Share of Myriad Genetics is 2026 -0.73 USD. EBITDA per Share of Myriad Genetics was 2025 -1.34 USD. It decreases by -45.91% higher compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Myriad Genetics Stock analysis

What does Myriad Genetics do? Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide. Myriad Genetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myriad Genetics stock

EBITDA per Share of Myriad Genetics is -0.73 USD in 2026.

EBITDA per Share of Myriad Genetics changed from -1.34 USD to -0.73 USD, representing a -45.91% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Myriad Genetics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Myriad Genetics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Myriad Genetics